- Home
- ABOS vs AGEN Comparison
ABOS vs AGEN Comparison
Compare ABOS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | AGEN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 126.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ABOS | AGEN |
|---|---|---|
| Price | $2.11 | $3.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $14.50 |
| AVG Volume (30 Days) | 154.4K | ★ 604.5K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $1.38 |
| 52 Week High | $2.46 | $7.34 |
Technical Indicators
Market Signals| Indicator | ABOS | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 31.67 |
| Support Level | $2.01 | $3.26 |
| Resistance Level | $2.39 | $4.00 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 50.93 | 30.49 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).